GLAXF News and Press, GlaxoSmithKline Plc From 06/08/22

Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. During a volatile quarter, the portfolio held up better than the Morningstar Global Markets ex-US Index...

Vivo Capital, a US-China healthcare investor, held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerati...

My portfolio, built specifically for my retirement ~20+ years from now, makes a strong pivot from my formerly diversified base to a more focused core. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping crea...

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...

GlaxoSmithKline plc (GSK) UBS Global Healthcare Conference Call May 24, 2022 09:15 ET Company Participants Kimberly Smith - Head of Global Research & Medical Strategy Conference Call Participants Laura Sutcliffe - UBS Presentation Laura Sutcliffe All right. Good morning, everyone. Welcome...

ImmunoGen is a promising turnaround equity that is approaching its inflection point in growth. Mirvetuximab is poised to gain approval toward yearend. In H2 this year, ImmunoGen is set to release a flurry of catalysts. For further details see: ImmunoGen: An Inflection Po...

Seth Klarman’s 13F portfolio value decreased from $10.13B to $9.30B this quarter. Baupost Group increased Fiserv, Dropbox, Encompass Health, Nuvation Bio, and ironSource while reducing Joby Aviation and dropping Pershing Square Tontine and NortonLifeLock. The portfolio cont...

Fisher's 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Nvidia, Intuit, Broadcom, Verizon, Uber, AMD, & Meta Platforms were increased while reducing Intel, Walmart, Walt Disney, Cisco, UnitedHealth, Starbucks & Visa this quarter. The top three positions ar...

Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...

Vir Biotechnology had obtained about $917.2 million of sotrovimab collaboration revenue in 2021; Expects about $1.1 billion in revenues with all doses delivered by 1st half of 2022. About 95% of patients who took VIR-2218 plus PEG-IFN-a achieved Hepatitis B surface antigen ((HBsA...